Navigation Links
Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
Date:4/11/2008

SAN DIEGO, California, April 11 /PRNewswire/ --

- Newly Established Organization Presents Data on Advancing Compounds at AACR -

Ortho Biotech Oncology Research & Development (ORD), a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., will announce results from studies of three innovative compounds--Hdm2, c-Met, and HDAC inhibitors --here at the American Association for Cancer Research (AACR) 2008 Annual Meeting.

"ORD is a new research and development organization that unites the biotechnology and pharmaceutical oncology efforts of several Johnson & Johnson companies with the goal of transforming cancer into a chronic or curable disease," said William Hait, M.D., Senior Vice President and Worldwide Head of Ortho Biotech Oncology Research & Development. "The new organization harnesses broad, multi-disciplinary capabilities and expertise in order to prioritize existing and emerging opportunities, align cancer treatment with modern cancer biology and improve patients' lives."

ORD's scientific approach to cancer examines the cancer cell and the surrounding tissue, or microenvironment. Previously, researchers often studied cancer as collections of malignant cells growing in isolation, but now understand cancer cells depend on interactions with the surrounding tissue to survive, grow and metastasize. ORD seeks to identify compounds which can inhibit or block the interaction cancer cells have with the surrounding tissues, which compromises the cancer's ability to survive.

The organization will combine the microenvironment disruptive agents (MDAs) resulting from this approach with classic treatments that directly target cancer cells. MDAs represent one of the most promising areas of drug discovery, and ORD has a pipeline of several investigational MDAs, including some of which are first-in-class and first-in-clinic.

Pre-clinical data presented at this year's AACR meeting demonstrate evidence of broad-spec
'/>"/>

SOURCE Ortho Biotech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa)
2. Osteotech to Present at the Canaccord Adams Small-Cap Orthopedics Conference in San Francisco
3. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
4. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
5. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
6. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
7. Symmetry Medical to Present at Canaccord Adams Small-Cap Orthopedics Conference
8. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
9. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
10. Progentix Orthobiology B.V. Closes Series A Financing Round
11. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industryā€¯ is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... 18, 2014 BioElectronics Corporation (OTC ... medical devices said that its EVP Dr. ... CEOLIVE.TV as part of its Executive Interview ... available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... investors the unique advantages of BioElectronics patented ...
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... -- TNI BioTech, Inc. (OTC-BB: TNIB) ("we" or the ... of innovative therapies for autoimmune diseases in emerging nations, ... notice of TNI BioTech,s annual meeting of September 4, ... Griffin , founder and CEO of TNI BioTech Inc. ... the Annual Meeting. On behalf of our employees and ...
Breaking Biology Technology:Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... 2010 , , , ... and Safety Endpoints , , , ... European Medicines Agency in,2010 , , , ... focused on,women,s reproductive medicine, announces positive Phase III data from its,second pivotal study (PEARL I) for its ...
... PARIS , June 2 Cellectis ... Frederic Paques, PhD, Chief Scientific Officer, Julianne Smith , ... genome surgery, and Feng Zhang , PhD, Research Director ... results on meganucleases and genome surgery at the FASEB ...
... ... Council survey examines consumer attitudes toward food technology. , ... Washington, DC (Vocus) Junw 2, 2010 -- ... survey found that consumers support the use of food biotechnology when they consider its ...
Cached Biology Technology:PregLem Announces Positive Phase III Results for Esmya(TM) 2PregLem Announces Positive Phase III Results for Esmya(TM) 3PregLem Announces Positive Phase III Results for Esmya(TM) 4Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering 2Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering 3Interest in Environment & Sustainability Prevails in Food Technology Survey 2Interest in Environment & Sustainability Prevails in Food Technology Survey 3Interest in Environment & Sustainability Prevails in Food Technology Survey 4Interest in Environment & Sustainability Prevails in Food Technology Survey 5
(Date:8/19/2014)... news release is available in German . ... get new information about the metabolism of plants can ... However, Erich Kombrink from the Max Planck Institute for ... the University of Duisburg-Essen adopt a different approach. They ... metabolic process like brake pads and prevent the downstream ...
(Date:8/19/2014)... Daylight was breaking over the central Pacific and ... about a dozen scientists strategized for the day ahead. ... to collect water samples around the southern Line Islands, ... gizmos and delicate machinery strewn throughout the 158-foot research ... research group to bring a DNA sequencer out into ...
(Date:8/18/2014)... , August 19, 2014 ... Ready biometric authentication in smart devices  ... (TEEs) for smart devices, and Fingerprint Cards AB ... availability of FIDO Ready™ secure biometric authentication on ... FPCs touch fingerprint sensors (FPC1020, FPC1021 and FPC1150) ...
Breaking Biology News(10 mins):Researchers block plant hormone 2Researchers block plant hormone 3Sequencing at sea 2Sequencing at sea 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4
... LOS ANGELES In research that one day may lead to ... disease, investigators at Childrens Hospital Los Angeles have identified PDGF ... epicardial cells, one type of cell that surrounds heart muscle ... September 21 in advance of the publication of the ...
... COLUMBIA, Mo. A cancer drug that benefits people ... teaching professor of oncology at the MU College of ... that examines the efficacy of Attaxol in dogs with ... by CritiTech, a Lawrence, Kan. drug development company. ...
... long encouraged by doctors as a supplement to support heart ... and colon cancer in mice in research led by Michigan ... Cancer Research . Jenifer Fenton, a food science and ... establishing a dose limit for docosahexaenoic acid (DHA), one of ...
Cached Biology News:Childrens Hospital LA discovers growth factor essential to epicardial cell function 2MU College of Veterinary Medicine to study efficacy of cancer drug in dogs 2Fish oil linked to increased risk of colon cancer in mice 2
... of large numbers of samples may be carried ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
Biology Products: